Common Side Effects of Casgevy
Casgevy (exagamglogene autotemcel), a CRISPR-based gene therapy for sickle cell disease and beta thalassemia, causes side effects mainly from the chemotherapy preconditioning and gene editing process. The most frequent include low blood cell counts (neutropenia, anemia, thrombocytopenia, leukopenia), occurring in over 90% of patients, often within weeks of treatment.[1][2] Other common ones (affecting 50%+ of patients) are fatigue, fever, headache, abdominal pain, nausea, musculoskeletal pain, chills, and mouth sores.[1]
Serious Risks and Long-Term Concerns
Infusion-related reactions happen in most patients, ranging from mild fever to severe anaphylaxis-like symptoms managed with supportive care.[1] Gene editing can trigger off-target mutations, though clinical trials showed no evidence of cancer in short-term follow-up (up to 2 years).[2][3] Preconditioning chemotherapy leads to infertility risks, so patients are advised to discuss fertility preservation beforehand.[1] Secondary malignancies occurred in 4% of trial patients, linked to conditioning rather than the therapy itself.[2]
How Side Effects Differ by Condition
In sickle cell patients (CLIMB-121 trial, n=31), 100% had grade 3+ cytopenias; vaso-occlusive crises dropped post-treatment but febrile neutropenia hit 97%.[2] Beta thalassemia patients (CLIMB-111, n=42) saw similar cytopenia rates (93-100%), with fewer transfusion-related issues long-term but high infection risk during recovery.[2] Kids under 12 had comparable profiles but shorter monitoring data.[1]
What Happens During Recovery
Cytopenias peak 3-4 weeks post-infusion and resolve by month 2 in most, though some persist longer.[1][2] Engraftment (new blood cell production) occurs around week 4-6, reducing infection and bleeding risks. Hospital stays average 5-14 days for monitoring; outpatient follow-up lasts years for durability and cancer screening.[3]
Patient-Reported Experiences
Real-world feedback highlights prolonged fatigue (months), hair loss from chemo, and emotional strain from isolation during neutropenia. Infections like pneumonia affected 20-30%; anti-infective prophylaxis is standard.[2] Vaso-occlusive pain relief motivates many, but 10-15% needed transfusions beyond month 3.[1]
[1]: Casgevy Prescribing Information (FDA)
[2]: NEJM: CLIMB Trials (2023)
[3]: FDA Approval Summary (2023)